Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.

Autor: Owen A. O'Connor, Hamlin, Paul A., Portlock, Carol, Moskowitz, Craig H., Noy, Ariela, Straus, David J., MacGregor-Cortelli, Barbara, Neylon, Ellen, Sarasohn, Debra, Dumetrescu, Otila, Mould, Diane R., Fleischer, Martin, Zelenetz, Andrew D., Sirotnak, Frank, Horwitz, Steven

Publikováno v: British Journal of Haematology; Nov2007, Vol. 139 Issue 3, p425-428, 4p, 1 Black and White Photograph, 1 Chart

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Autor: O'Connor OA; Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. oconnoro@mskcc.org, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2005 Feb 01; Vol. 23 (4), pp. 676-84. Date of Electronic Publication: 2004 Dec 21.